{"entity":{"id":"nct05390710","kind":"trial","name":"PhI to Solid Tumors and PhII to Locally Advanced or mTNBC","aka":[],"tldr":"A phase 1 trial of Afuresertib run by Laekna Limited, completed.","summary":"PhI to Solid Tumors and PhII to Locally Advanced or mTNBC is a phase 1 interventional study registered as NCT05390710 by Laekna Limited, with 21 participants enrolled, started 2021-06-12, primary completion reached 2023-12-11. Conditions recorded: Solid Tumor, TNBC - Triple-Negative Breast Cancer. Interventions recorded: LAE005 + Afuresertib + Nab-Paclitaxel.","status":"completed","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT05390710","url":"https://clinicaltrials.gov/study/NCT05390710"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["afuresertib"],"companies":["laekna-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05390710","phase":"1","setting":"A PhI Dose Escalation Study of LAE005+Afuresertib+Nab_Paclitaxel in Advanced Solid Tumors and PhII Study to Evaluate the Safety and Efficacy of LAE005+Afur+Nab_Paclitaxel or LAE005/Afur+Nab-Paclitaxel in Locally Advanced or mTNBC","sponsor":"Laekna Limited","enrolled":21,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05390710/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"afuresertib","kind":"drug","name":"Afuresertib","route":"/drugs/afuresertib/"}],"company":[{"id":"laekna-therapeutics","kind":"company","name":"Laekna Therapeutics","route":"/companies/laekna-therapeutics/"}]}}